Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222973 | 0.79 | TGFBR1 (0.50) | TGFBR1MTORACVR1BMAPK14RIPK2 | |
| SCHEMBL6182965 | 0.78 | TGFBR1 (0.46) | TGFBR1ACVR1BMAPK14SMOPDE10A | |
| SCHEMBL6327636 | 0.74 | TGFBR1 (0.40) | TGFBR1MTORACVR1BMAPK14RIPK2 | |
| SCHEMBL6182397 | 0.72 | SMO (0.40) | TGFBR1ACVR1BMAPK14SMOFFAR1 | |
| SCHEMBL5907466 | 0.71 | TGFBR1 (0.41) | TGFBR1MAPK14RIPK2 | |
| SCHEMBL6223211 | 0.71 | TGFBR1 (0.54) | TGFBR1MTORACVR1BMAPK14RIPK2 | |
| SCHEMBL6325331 | 0.70 | TGFBR1 (0.56) | TGFBR1MTORACVR1BMAPK14RIPK2 | |
| SCHEMBL6328925 | 0.69 | TGFBR1 (0.67) | TGFBR1MTORACVR1BMAPK14RIPK2 | |
| SCHEMBL5956566 | 0.68 | TGFBR1 (0.52) | TGFBR1MAPK14RIPK2 | |
| SCHEMBL5790048 | 0.67 | TGFBR1 (0.38) | TGFBR1MAPK14SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | DODIC NERINA | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245520-A1 | 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors | SMAD2, SMAD3, ALK | TGFBR1 7/4885MTOR 77/4885ACVR1B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.